ICONIC-LEAD: Oral Icotrokinra Clears Skin in 75% of Adolescents with Plaque Psoriasis
Key Takeaways
75% of adolescents achieved completely clear skin with icotrokinra by week 24 in the ICONIC-LEAD study.
Icotrokinra had a favorable safety profile with fewer adverse events than placebo.
Icotrokinra, an investigational oral IL-23 receptor antagonist, led to completely clear skin in 75% of adolescents with moderate-to-severe plaque psoriasis by week 24, according to results presented at the 2025 World Congress of Pediatric Dermatology.
In a subgroup analysis from the Phase 3 ICONIC-LEAD study— the first registrational trial to simultaneously evaluate adolescents and adults—adolescents treated with once-daily icotrokinra achieved high levels of skin clearance. The trial enrolled 66 adolescent patients aged 12 years or older (total patient population, N=684).
According to the results, by week 16, 84.1% of adolescent participants achieved an Investigator’s Global Assessment (IGA) score of 0 or 1, and 70.5% achieved a ≥90% reduction in Psoriasis Area and Severity Index (PASI 90). The outcomes improved through week 24, with 86.4% achieving IGA 0/1 and 88.6% reaching PASI 90. A total of 75% of adolescents achieved IGA 0 and 63.6% achieved PASI 100.
“These data demonstrate impressive efficacy rates, showing the promise of this novel therapeutic option in the treatment of adolescents with moderate-to-severe plaque psoriasis who've often not yet received an advanced therapy,” said Lawrence Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego and study presenter, in a press release.
At week 16, 50% of adolescents on icotrokinra experienced at least one adverse event compared to 73% in the placebo group, with no new safety signals identified.
“These data underscore the promise of next-generation therapies and the potential for icotrokinra to offer adolescents the unique combination of a favorable safety profile and complete skin clearance in a once-daily pill,” said Liza O’Dowd, Vice President, Immunodermatology Disease Area Lead at Johnson & Johnson Innovative Medicine, in a press release.
Sources:
Eichenfield Lawrence, et al. Presented at the 2025 World Congress of Pediatric Dermatology.
Johnson & Johnson press release, April 10, 2025.